Recommendation of the President – Ospolot (sultiam)
On 30 Oxtober 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 162/2025 on the validity of granting approvals for the reimbursement of the medicinal product Ospolot (sultiam) for the following indications: epilepsy, drug-resistant epilepsy, drug-resistant epilepsy in the course of Rett syndrome